{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T11:21:40Z","timestamp":1770549700274,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,31]]},"DOI":"10.7759\/cureus.81491","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T10:02:19Z","timestamp":1743415339000},"source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Potential Stimuli and Deterrents of Varicella-Zoster Viral Reactivation: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Alexandra","family":"Lens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel","family":"Sibaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly","family":"Snytte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukriti","family":"Prashar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria","family":"Sobczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Muralidhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Demory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.038","article-title":"Recurrent herpes zoster in the Shingles Prevention Study: are second episodes caused by the same varicella-zoster virus strain?","volume":"38","author":"Harbecke R","year":"2020","unstructured":"Harbecke R, Jensen NJ, Depledge DP, et al.. Recurrent herpes zoster in the Shingles Prevention Study: are second episodes caused by the same varicella-zoster virus strain?. Vaccine. 2020, 38:150-7. 10.1016\/j.vaccine.2019.10.038","journal-title":"Vaccine"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review","volume":"60","author":"Lacaille-Dubois MA","year":"2019","unstructured":"Lacaille-Dubois MA. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review. Phytomedicine. 2019, 60:152905. 10.1016\/j.phymed.2019.152905","journal-title":"Phytomedicine"},{"key":"ref3","article-title":"Shingrix for herpes zoster: a review","volume":"24","author":"Shah RA","year":"2019","unstructured":"Shah RA, Limmer AL, Nwannunu CE, Patel RR, Mui UN, Tyring SK. Shingrix for herpes zoster: a review. Skin Therapy Lett. 2019, 24:5-7.","journal-title":"Skin Therapy Lett"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.021","article-title":"Effectiveness of herpes zoster vaccination in an older United Kingdom population","volume":"36","author":"Walker JL","year":"2018","unstructured":"Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018, 36:2371-7. 10.1016\/j.vaccine.2018.02.021","journal-title":"Vaccine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gly150","article-title":"Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older","volume":"74","author":"Curran D","year":"2019","unstructured":"Curran D, Oostvogels L, Heineman T, et al.. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019, 74:1231-8. 10.1093\/gerona\/gly150","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117186","article-title":"Deficits in ascending and descending pain modulation pathways in patients with postherpetic neuralgia","volume":"221","author":"Li H","year":"2020","unstructured":"Li H, Li X, Feng Y, Gao F, Kong Y, Hu L. Deficits in ascending and descending pain modulation pathways in patients with postherpetic neuralgia. Neuroimage. 2020, 221:117186. 10.1016\/j.neuroimage.2020.117186","journal-title":"Neuroimage"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.095","article-title":"Patient report of herpes zoster pain: incremental benefits of zoster vaccine live","volume":"37","author":"Bruxvoort KJ","year":"2019","unstructured":"Bruxvoort KJ, Liang AS, Harpaz R, et al.. Patient report of herpes zoster pain: incremental benefits of zoster vaccine live. Vaccine. 2019, 37:3478-84. 10.1016\/j.vaccine.2019.04.095","journal-title":"Vaccine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham AL","year":"2018","unstructured":"Cunningham AL, Heineman TC, Lal H, et al.. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018, 217:1750-60. 10.1093\/infdis\/jiy095","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman MN","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, et al.. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005, 352:2271-84. 10.1056\/NEJMoa051016","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Anderson TC","year":"2022","unstructured":"Anderson TC, Masters NB, Guo A, et al.. Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022, 71:80-4. 10.15585\/mmwr.mm7103a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin MJ","year":"2018","unstructured":"Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018, 128:4429-40. 10.1172\/JCI121484","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246086","article-title":"Herpes zoster in older adults in Ontario, 2002-2016: investigating incidence and exploring equity","volume":"16","author":"Buchan SA","year":"2021","unstructured":"Buchan SA, Daneman N, Wang J, et al.. Herpes zoster in older adults in Ontario, 2002-2016: investigating incidence and exploring equity. PLoS One. 2021, 16:e0246086. 10.1371\/journal.pone.0246086","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-20-12","article-title":"Scoping reviews (2020 version)","author":"Peters MDJ","year":"2020","unstructured":"Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Scoping reviews (2020 version). JBI Reviewer's Manual. Aromataris E, Munn Z (ed): JBI, Adelaide, Australia; 2020. 10.46658\/JBIMES-20-12"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20200473","article-title":"Risk of herpes zoster in relation to body mass index among residents aged \u226550 years: the Shozu Herpes Zoster Study","volume":"32","author":"Kawahira K","year":"2022","unstructured":"Kawahira K, Imano H, Yamada K, et al.. Risk of herpes zoster in relation to body mass index among residents aged \u226550 years: the Shozu Herpes Zoster Study. J Epidemiol. 2022, 32:370-5. 10.2188\/jea.JE20200473","journal-title":"J Epidemiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17072228","article-title":"Association between chronic interstitial cystitis and herpes zoster","volume":"17","author":"Hsu CY","year":"2020","unstructured":"Hsu CY, Lin CL, Kao CH. Association between chronic interstitial cystitis and herpes zoster. Int J Environ Res Public Health. 2020, 17:10.3390\/ijerph17072228","journal-title":"Int J Environ Res Public Health"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046891","article-title":"Association between de Quervain syndrome and herpes zoster: a population-based cohort study","volume":"11","author":"Hsu CY","year":"2021","unstructured":"Hsu CY, Ke DS, Lin CL, Kao CH. Association between de Quervain syndrome and herpes zoster: a population-based cohort study. BMJ Open. 2021, 11:e046891. 10.1136\/bmjopen-2020-046891","journal-title":"BMJ Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab027","article-title":"Associations of lifestyle and anthropometric factors with the risk of herpes zoster: a nationwide population-based cohort study","volume":"190","author":"Schmidt SA","year":"2021","unstructured":"Schmidt SA, S\u00f8rensen HT, Langan SM, Vestergaard M. Associations of lifestyle and anthropometric factors with the risk of herpes zoster: a nationwide population-based cohort study. Am J Epidemiol. 2021, 190:1064-74. 10.1093\/aje\/kwab027","journal-title":"Am J Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-022-05929-y","article-title":"Chondromalacia patella increases the risk of herpes zoster: a population-based study","volume":"23","author":"Chen CH","year":"2022","unstructured":"Chen CH, Cheng YC, Yang HY, Tsai CF, Hsu CY, Ke DS, Hsieh WC. Chondromalacia patella increases the risk of herpes zoster: a population-based study. BMC Musculoskelet Disord. 2022, 23:961. 10.1186\/s12891-022-05929-y","journal-title":"BMC Musculoskelet Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03847-5","article-title":"Herpes zoster in patients with sciatica","volume":"21","author":"Ke DS","year":"2020","unstructured":"Ke DS, Hsu CY, Lin CL, Hsu CY, Kao CH. Herpes zoster in patients with sciatica. BMC Musculoskelet Disord. 2020, 21:813. 10.1186\/s12891-020-03847-5","journal-title":"BMC Musculoskelet Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13055","article-title":"Influenza vaccine and subsequent development of zoster","volume":"17","author":"Wei KC","year":"2023","unstructured":"Wei KC, Chang YC, Huang YT. Influenza vaccine and subsequent development of zoster. Influenza Other Respir Viruses. 2023, 17:e13055. 10.1111\/irv.13055","journal-title":"Influenza Other Respir Viruses"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259942","article-title":"Plantar fascial fibromatosis and herpes zoster","volume":"16","author":"Hsu CY","year":"2021","unstructured":"Hsu CY, Ke DS, Lin CL, Kao CH. Plantar fascial fibromatosis and herpes zoster. PLoS One. 2021, 16:e0259942. 10.1371\/journal.pone.0259942","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32926","article-title":"Radiation therapy and the risk of herpes zoster in patients with cancer","volume":"126","author":"Shimizuguchi T","year":"2020","unstructured":"Shimizuguchi T, Sekiya N, Hara K, et al.. Radiation therapy and the risk of herpes zoster in patients with cancer. Cancer. 2020, 126:3552-9. 10.1002\/cncr.32926","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register","volume":"81","author":"Redeker I","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J, et al.. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022, 81:41-7. 10.1136\/annrheumdis-2021-220651","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017430","article-title":"The risk of herpes zoster virus infection in patients with depression: a longitudinal follow-up study using a national sample cohort","volume":"98","author":"Choi HG","year":"2019","unstructured":"Choi HG, Kim EJ, Lee YK, Kim M. The risk of herpes zoster virus infection in patients with depression: a longitudinal follow-up study using a national sample cohort. Medicine (Baltimore). 2019, 98:e17430. 10.1097\/MD.0000000000017430","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231974","article-title":"Seropositivity of selected chronic infections and different measures of obesity","volume":"15","author":"Freuer D","year":"2020","unstructured":"Freuer D, Linseisen J, Waterboer T, et al.. Seropositivity of selected chronic infections and different measures of obesity. PLoS One. 2020, 15:e0231974. 10.1371\/journal.pone.0231974","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.08.022","article-title":"Ultraviolet radiation exposure and the risk of herpes zoster in three prospective cohort studies","volume":"95","author":"Kawai K","year":"2020","unstructured":"Kawai K, VoPham T, Drucker A, Curhan SG, Curhan GC. Ultraviolet radiation exposure and the risk of herpes zoster in three prospective cohort studies. Mayo Clin Proc. 2020, 95:283-92. 10.1016\/j.mayocp.2019.08.022","journal-title":"Mayo Clin Proc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1742-5","article-title":"VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs","volume":"20","author":"Schub D","year":"2018","unstructured":"Schub D, Assmann G, Sester U, Sester M, Schmidt T. VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Arthritis Res Ther. 2018, 20:252. 10.1186\/s13075-018-1742-5","journal-title":"Arthritis Res Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt J","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al.. Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019, 21:89. 10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17103592","article-title":"Risk of herpes zoster in patients with adhesive capsulitis of the shoulder","volume":"17","author":"Hsu CY","year":"2020","unstructured":"Hsu CY, Ke DS, Lin CL, Kao CH. Risk of herpes zoster in patients with adhesive capsulitis of the shoulder. Int J Environ Res Public Health. 2020, 17:10.3390\/ijerph17103592","journal-title":"Int J Environ Res Public Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250724","article-title":"Incidence and time trends of herpes zoster among patients with head and neck cancer who did and did not undergo radiotherapy: a population-based cohort study","volume":"16","author":"Lee PY","year":"2021","unstructured":"Lee PY, Lai JN, Chiu LT, Wei YT. Incidence and time trends of herpes zoster among patients with head and neck cancer who did and did not undergo radiotherapy: a population-based cohort study. PLoS One. 2021, 16:e0250724. 10.1371\/journal.pone.0250724","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.008","article-title":"Effectiveness of the herpes zoster vaccine Zostavax\u00ae in Stockholm County, Sweden","volume":"37","author":"Blom K","year":"2019","unstructured":"Blom K, Yin L, Arnheim-Dahlstr\u00f6m L. Effectiveness of the herpes zoster vaccine Zostavax\u00ae in Stockholm County, Sweden. Vaccine. 2019, 37:4401-6. 10.1016\/j.vaccine.2019.06.008","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab629","article-title":"The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70","volume":"74","author":"Boutry C","year":"2022","unstructured":"Boutry C, Hastie A, Diez-Domingo J, et al.. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022, 74:1459-67. 10.1093\/cid\/ciab629","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2002085","article-title":"Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany","volume":"17","author":"Curran D","year":"2021","unstructured":"Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021, 17:5296-303. 10.1080\/21645515.2021.2002085","journal-title":"Hum Vaccin Immunother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16917","article-title":"Recombinant zoster vaccine is efficacious and safe in frail individuals","volume":"69","author":"Curran D","year":"2021","unstructured":"Curran D, Kim JH, Matthews S, et al.. Recombinant zoster vaccine is efficacious and safe in frail individuals. J Am Geriatr Soc. 2021, 69:744-52. 10.1111\/jgs.16917","journal-title":"J Am Geriatr Soc"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa424","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials","volume":"60","author":"Dagnew AF","year":"2021","unstructured":"Dagnew AF, Rausch D, Herv\u00e9 C, Zahaf T, Levin MJ, Schuind A. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021, 60:1226-33. 10.1093\/rheumatology\/keaa424","journal-title":"Rheumatology (Oxford)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1859321","article-title":"The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults \u2265 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials","volume":"17","author":"Kim JH","year":"2021","unstructured":"Kim JH, Diaz-Decaro J, Jiang N, et al.. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults \u2265 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021, 17:2050-7. 10.1080\/21645515.2020.1859321","journal-title":"Hum Vaccin Immunother"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.017","article-title":"Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States","volume":"128","author":"Lu A","year":"2021","unstructured":"Lu A, Sun Y, Porco TC, Arnold BF, Acharya NR. Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States. Ophthalmology. 2021, 128:1699-707. 10.1016\/j.ophtha.2021.04.017","journal-title":"Ophthalmology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.08.037","article-title":"Assessing the effectiveness of zoster vaccine live: a retrospective cohort study using primary care data in the United Kingdom","volume":"36","author":"Matthews I","year":"2018","unstructured":"Matthews I, Lu X, Dawson H, Bricout H, O'Hanlon H, Yu E, Nozad B. Assessing the effectiveness of zoster vaccine live: a retrospective cohort study using primary care data in the United Kingdom. Vaccine. 2018, 36:7105-11. 10.1016\/j.vaccine.2018.08.037","journal-title":"Vaccine"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.056","article-title":"Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study","volume":"39","author":"Sun Y","year":"2021","unstructured":"Sun Y, Jackson K, Dalmon CA, et al.. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021, 39:3974-82. 10.1016\/j.vaccine.2021.05.056","journal-title":"Vaccine"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab121","article-title":"Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study","volume":"73","author":"Sun Y","year":"2021","unstructured":"Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study. Clin Infect Dis. 2021, 73:949-56. 10.1093\/cid\/ciab121","journal-title":"Clin Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.028","article-title":"Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry\/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials","volume":"37","author":"Willer DO","year":"2019","unstructured":"Willer DO, Oostvogels L, Cunningham AL, et al.. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry\/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019, 37:6262-7. 10.1016\/j.vaccine.2019.09.028","journal-title":"Vaccine"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1627818","article-title":"Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials","volume":"15","author":"Oostvogels L","year":"2019","unstructured":"Oostvogels L, Heineman TC, Johnson RW, et al.. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019, 15:2865-72. 10.1080\/21645515.2019.1627818","journal-title":"Hum Vaccin Immunother"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30234-7","article-title":"Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study","volume":"3","author":"Amirthalingam G","year":"2018","unstructured":"Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, Ramsay M. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health. 2018, 3:e82-90. 10.1016\/S2468-2667(17)30234-7","journal-title":"Lancet Public Health"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter R","year":"2018","unstructured":"Baxter R, Bartlett J, Fireman B, et al.. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2018, 187:161-9. 10.1093\/aje\/kwx245","journal-title":"Am J Epidemiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.004","article-title":"Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention","volume":"37","author":"Klein NP","year":"2019","unstructured":"Klein NP, Bartlett J, Fireman B, et al.. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019, 37:5422-7. 10.1016\/j.vaccine.2019.07.004","journal-title":"Vaccine"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.46038","article-title":"Efficacy of intermittent epidural dexamethasone bolus for zoster-associated pain beyond the acute phase","volume":"17","author":"Choi EM","year":"2020","unstructured":"Choi EM, Chung MH, Jun JH, et al.. Efficacy of intermittent epidural dexamethasone bolus for zoster-associated pain beyond the acute phase. Int J Med Sci. 2020, 17:1811-8. 10.7150\/ijms.46038","journal-title":"Int J Med Sci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/1744806921999924","article-title":"Genome-wide association study identifies candidate loci associated with chronic pain and postherpetic neuralgia","volume":"17","author":"Nishizawa D","year":"2021","unstructured":"Nishizawa D, Iseki M, Arita H, et al.. Genome-wide association study identifies candidate loci associated with chronic pain and postherpetic neuralgia. Mol Pain. 2021, 17:1744806921999924. 10.1177\/1744806921999924","journal-title":"Mol Pain"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281664-exploring-the-potential-stimuli-and-deterrents-of-varicella-zoster-viral-reactivation-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T10:02:30Z","timestamp":1743415350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281664-exploring-the-potential-stimuli-and-deterrents-of-varicella-zoster-viral-reactivation-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.81491","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}